文献速递炎症性肠病肝病

原发性硬化性胆管炎与结肠炎:复杂关系

PSC and colitis: A complex relationship.
PubMed 文献 · Hepatology · 2025-01-22

综述总结原发性硬化性胆管炎(PSC)与炎症性肠病(IBD)的肠-肝轴关系,指出PSC-IBD是独立于溃疡性结肠炎和克罗恩病的IBD类型,临床可观察到的肠道病变占60%-80%,分子层面几乎所有PSC患者存在潜在结肠炎,二者可相互加重也可互相保护。

要点

  • PSC-IBD是独立IBD类型,与溃疡性结肠炎和克罗恩病并存。
  • 临床可观察到的肠道病变占PSC患者的60%-80%。
  • 分子层面几乎所有PSC患者存在潜在结肠炎。

核心结论

  • PSC-IBD是独立于溃疡性结肠炎和克罗恩病的IBD类型,肝与肠可相互加重也可互相保护,关系复杂。

研究设计与样本

  • 综述总结PSC-IBD中肠-肝轴的当前知识、风险分层与治疗新视角及知识空白。

主要发现

  • 临床可观察到的肠道病变占PSC患者的60%-80%。
  • 分子层面几乎所有PSC患者存在潜在结肠炎。
  • 硬化性胆管炎在某些情况下可保护肠道,结肠炎在某些情况下可改善肝脏病理。
  • 遗传易感性、肠道菌群变化、胆汁酸代谢改变和免疫细胞迁移是疑似参与因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary sclerosing cholangitis is one of the most challenging conditions in hepatology, and due to our limited understanding of its pathogenesis, no causal therapies are currently available. While it was long assumed that a minority of people with inflammatory bowel disease (IBD) also develop primary sclerosing cholangitis (PSC), which is sometimes labeled an extraintestinal manifestation of IBD, the clinical phenotype, genetic, and intestinal microbiota associations strongly argue for PSC-IBD being a distinct form of IBD, existing alongside ulcerative colitis and Crohn's disease. In fact, the liver itself could contribute to intestinal pathology, clinically overt in 60%-80% of patients. Recent studies suggested that on a molecular level, almost all people with PSC have underlying colitis. The extent to which the liver and gut influence each other clinically and in terms of disease progression has not yet been conclusively revealed. However, while it seemed intuitive that the 2 diseases have a negative influence on each other, evidence suggests that sclerosing cholangitis can also be protective for the gut and that colitis can, in certain settings, ameliorate liver pathology. This underscores the complex pathophysiological relationships, where factors such as genetic predisposition, changes in the intestinal microbiota, altered bile acid metabolism, and immune cell migration are among the suspected contributors. PSC is an emerging disease with a significant impact on the health-related quality of life of affected people. With this review, we aim to summarize the current knowledge on the gut-liver axis in PSC-IBD, provide new perspectives on risk stratification and treatment, and identify gaps in our current knowledge. Our understanding of this complex relationship will therefore help to design clinical trials and shape the future therapy of PSC-IBD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Horst LJ, Kempski J, Walmsley M, et al. PSC and colitis: A complex relationship. Hepatology. 2025. PMID: 39841598. doi:10.1097/HEP.0000000000001236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。